Pluristem Therapeutics, Inc. (PSTI) News
Filter PSTI News Items
PSTI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PSTI News From Around the Web
Below are the latest news stories about PLURISTEM THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTI as an investment opportunity.
10 Biotech Penny Stocks with Growth CatalystsIn this article, we discuss 10 biotech penny stocks with growth catalysts. If you want to see some more stocks in this selection, check out 5 Biotech Penny Stocks with Growth Catalysts. According to Global Market Insights, the market for biotech in 2020 was valued at $497 billion, and it is forecasted to grow to […] |
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New PartnershipClosing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: https://livestream.com/accounts/27896496/events/10177910 HAIFA, Israel, March 28, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”), a leading biotechnology company, and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today announced that Pl |
Pluristem''s PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant PatientsPluristem Therapeutics Inc (NASDAQ: PSTI ) announced final results from its hematology Phase 1 study of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). Data collated 12 months post-treatment with PLX-R18 demonstrate that PLX-R18 was well-tolerated with … Full story available on Benzinga.com |
Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialPluristem Therapeutics (PSTI) reported final results from a phase 1 trial of intramuscular injections of PLX-R18 in patients with incomplete hematopoietic recovery following… |
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood TransfusionsResults show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a favorable safety profile.PLX-R18 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of graft failure and incomplete hematopoietic recovery following HCT and the prevention and treatment of acute radiat |
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint VentureEyal Rosenthal (photo credit Jim Vetter) Eyal Rosenthal, CEO of Tnuva and Pluristem's new joint venture. Photographed by Jim Vetter. HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufact |
Pluristem CEO Issues Shareholder UpdateHAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay. Dear Shareholders, As I look ahead, I am more confident about the direction of Pluristem than ever before. We believe that our state-of-the-art cell expansion platform has the potential for high demand in the medical field and beyond. Our proven technology |
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food PlatformPluristem officially closed a deal with Israel’s largest food brand Tnuva on February 24 2022, cementing an innovative partnership in the fast-growing industry of food techPluristem and Tnuva are proven pioneers in cell culture technology and consumer food branding, with 100+ years of combined expertise in their fieldsThe joint venture closes at a pre-money valuation of $40 million, with Tnuva investing $7.5 million HAIFA, Israel, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Leading biotechnology company P |
15 Worst Stock Picks of Cathie WoodIn this article, we discuss the 15 worst stock picks of Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to the 5 Worst Stock Picks of Cathie Wood. Cathie Wood, the chief ARK Investment Management, is often hailed as the champion of “disruptive innovation” at the stock market. […] |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayI hope you enjoyed the long weekend, but it's time to get back into investing with the biggest pre-market stock movers for Tuesday! |